Alloimmunity (sometimes called isoimmunity) is an immune response to nonself antigens from members of the same species, which are called alloantigens or isoantigens. Two major types of alloantigens are blood group antigens and histocompatibility antigens. In alloimmunity, the body creates antibodies against the alloantigens, attacking transfused blood, allotransplanted tissue, and even the fetus in some cases. Alloimmune (isoimmune) response results in graft rejection, which is manifested as deterioration or complete loss of graft function. In contrast, autoimmunity is an immune response to the self's own antigens. (The allo- prefix means "other", whereas the auto- prefix means "self".) Alloimmunization (isoimmunization) is the process of becoming alloimmune, that is, developing the relevant antibodies for the first time.
Singapore Health Services Pte Ltd.
http://www.singhealth.com.sg
|
Part of MOH Holdings Pte Ltd., Singapore Health Services Pte Ltd. is a Singaporean company located in Singapore. The firm provides medical services. Ivy Ng is the CEO, in this role since 2012.
Part of Opthea Ltd., Vegenics Pty Ltd. is a company headquartered in Australia that provides medical research, development and commercialization of biologics drugs. On August 14, 2008 Opthea Ltd. acquired Vegenics Pty Ltd. for $5.06 million.
Drug
Medical research
Dendritic cell
Cell sorting
Biochip
Flow cytometry
Biomedical engineering
Optoelectronics
Biobank
Microfluidics
Blood cell
Cell signaling
Biochemistry
Biomedicine
Biotechnology
Glaxosmithkline Istrazivacki Centar Zagreb doo
http://www.glaxosmithkline.hr
|
Cerus Corporation is a biomedical products company focused in the field of blood safety. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. In the United States, Cerus is seeking regulatory approval of the INTERCEPT Blood System for plasma and platelets. The INTERCEPT red blood cell system is in clinical development.
Platelet
Automation
Medical equipment
Plasmapheresis
Blood plasma
Hematology
Red blood cell
Blood transfusion
Therapeutic plasma exchange
Viral Inactivation
Biotechnology
Blood collection
Biomedicine
Blood cell
Hemovigilance
Blood product
Clinical trial
Hospital bed
Bionics
Plasma derivative
AutoImmune, Inc.
http://www.autoimmuneinc.com
|
AutoImmune, Inc. develop products to treat autoimmune and other cell-mediated inflammatory conditions. Its products are based on a biological mechanism known as oral tolerance, which provides tissue specific immunosuppression without toxicity or significant side effects. The company was founded in September 1988 and is headquartered in Pasadena, CA.
Immunosuppression
Side effect
Biopharmaceutical
Toxicity
Tissue specific
Botanical drug
Herb
Annexon, Inc.
http://www.annexonbio.com
|
Annexon is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye. The company’s pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. The company’s first product candidate, ANX005, is a full-length monoclonal antibody formulated for intravenous administration in autoimmune and neurodegenerative disorders. The company’s second product candidate, ANX007, is a monoclonal antibody Fab formulated for intravitreal administration for the treatment of neurodegenerative ophthalmic disorders. Annexon is advancing its current programs while evaluating additional orphan and large market indications. Annexon is deploying a disciplined, biomarker-driven development strategy designed to establish that its product candidates are engaging the target at a well-tolerated therapeutic dose in the intended patient tissue.
Drug development
Biology
Medicine
Pharmacy and Therapeutics
Drug discovery
Huntington's disease
Parkinson's disease
Multiple sclerosis
Glaucoma
Clinical trial
Drug
Biotechnology
Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp. engages in the research, development, and distribution of vaccines, prescription drugs, and animal health products. The company is headquartered in Whitehouse Station, NJ.
Prescription drug
Medicine
Stroke
Cardiology
Oncology drugs
Neurology
Cancer immunotherapy
Monoclonal antibody
Cardiovascular agent
Immunotherapy
Toxoid
Endothelin receptor antagonist
Prostacyclin
Contraceptive implant
Anticoagulant
Conjugate vaccine
Allergy drugs
Albiglutide
Adenoid cystic carcinoma
Mometasone/formoterol
BioArray Solutions Ltd. develops and manufactures products for transfusion and transplantation medicine. Its solutions proprietary technology platform combines semiconductor technology, micro particle chemistry, and molecular biology to bring unparalleled flexibility and performance to quantitative DNA and protein analysis. The company was founded in 1997 and is headquartered in Warren, NJ.
Pharmacy
Medicine
Transplantation medicine
Molecular biology
DNA
Semiconductor
Shenzhen MingSight Relin Pharmaceuticals Co Ltd
http://www.mingsight.com
|
Mingsight, an ophthalmic medical drug developer, has initiated a clinical trial of the original innovative drug MS-553 in patients with diabetic retinopathy. This study is the world's first clinical trial of MS-553 in this indication. In the field of CLL treatment, MS-533 can be used alone or in combination with ibrutinib, BCL-2, etc., initially showing outstanding clinical value and market potential in the treatment of patients with C481S and PLCG2 mutations; in the field of DME treatment, MS-533 can be taken orally to achieve enrichment in the retina of the fundus, avoiding the need for vitreous injection of drugs such as ranibizumab, and clinical data such as BCVA/CRT of patients also initially show the efficacy of the product.
ViaCyte is a preclinical therapeutic company specializing in regenerative medicine therapies for diabetes. Their therapy is based on the differentiation of stem cells into pancreatic beta-cell precursors, with subcutaneous implantation in an encapsulation device. Data in their publications demonstrate that these cells can produce therapeutically relevant levels of insulin in response to blood glucose, and sustain diabetic animals. Their goal is a product which can free both Type 1 and Type 2 patients with diabetes from insulin dependence on a long-term basis, while reducing or eliminating hypoglycemic, microvasculature, and weight-related cardiovascular complications.
Stem cell
Diabetes Therapy
Medicine
Pharmacy and Therapeutics
Regenerative medicine
Insulin
Cardiovascular Complication
Induced pluripotent stem cell
Embryonic stem cell
Stem-cell therapy
Adult stem cell
Cell
Biopharmaceutical
Progenitor cell
Cord blood
Blood stem cell
Umbilical Cord Blood Stem Cell
Stem cell line
Tolerx, Inc. develops novel therapies focusing on modulating T-cell activities for treating autoimmune diseases, diabetes, and cancer. The company's products include otelixizumab, a targeted T-cell immunomodulator for treating type 1 diabetes; MTRX1011A, an anti-CD4 antibody for treating autoimmune indications; and TRX518 and TRX385, pre-clinical candidates that focuses on optimizing immune responses for treating cancer and chronic viral diseases. Tolerx, Inc., formerly known as TolerRx, Inc., was founded in 2000 and is based in Cambridge, Massachusetts.
Autoimmune disease
Otelixizumab
Type 1 diabetes
Viral disease
Antibody
Cancer
The Board of Regents of The University of Texas System
The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.
Oncogene
Cancer immunotherapy
Oncology drugs
University Health Network
University Health Network (UHN) is a healthcare and medical research organization in Toronto, Ontario, Canada. It is the largest such research organization in Canada and North America, ranking first in Canada for total research funding. It was named Canada's top research hospital by Research Infosource in 2015, 2016 and 2017. It was created in 1986 by the Government of Ontario through the merger of four major hospitals: Toronto General Hospital, Toronto Western Hospital, with the Princess Margaret Cancer Centre, and the Toronto Rehabilitation Institute merged in with The Toronto Hospital in 1999 and the name changed to the University Health Network. All four hospitals are affiliated with the Faculty of Medicine at the University of Toronto and serve as teaching hospitals for resident physicians, nurses, and other healthcare professions. UHN also operates The Michener Institute, an applied health sciences college that opened in 1958.
Glaxo Group Ltd.
https://www.gsk.com/en-gb
|
Glaxo Group Ltd. operates through its subsidiary Glaxo Laboratories Ltd. that engages in the production of food products for infants such as Ostermilk, Complan, Casilan, Farex. Glaxo Group Ltd. was formerly known as Glaxo Laboratories Ltd. and changed its name to Glaxo Group Ltd. in 1962. The company is based in Brentford, United Kingdom. Glaxo Group Ltd. operates as a subsidiary of Glaxosmithkline plc.
Regents of the University of California
The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).
Pathology
Companion diagnostic
Kymab is a clinical-stage biopharmaceutical company developing fully human monoclonal antibody therapeutics with a focus on immune-mediated diseases and immuno-oncology using its proprietary, integrated platforms collectively called IntelliSelect®. Kymab’s IntelliSelect Transgenic platforms contain a full diversity of human antibodies, making them the most comprehensive antibody platforms available.
The company was founded in 2010 and is based in Cambridge, the United Kingdom.
Monoclonal antibody
Medicine
Medical equipment
Pharmacy and Therapeutics
Drug
Biopharmaceutical
Lymphocyte
Biotechnology
Drug target
Oncology drugs
Immune system
Biomedicine
Immunotherapy
Drug discovery
Drug development
Regulatory T cell
Biochemistry
Psoriasis
CD28
Pembrolizumab
True North Therapeutics, Inc.
http://www.truenorthrx.com
|
True North Therapeutics is a pioneering biotechnology company selectively inhibiting the Complement pathway for diseases of high unmet clinical need. The company’s lead monoclonal antibody, TNT009, targets the Classical Complement pathway, enabling selective inhibition of downstream phagocytosis, inflammation, and cell lysis. True North is currently focused on Complement-mediated rare diseases in the hematologic, kidney transplant, dermatology, and neurological space. True North was formed in 2013 as a spin-out of iPierian.
Immunotherapy
Clinical trial
Medicine
Classical complement pathway
Selective inhibition
Phagocytosis
Biotechnology
Lysis
Rare disease
Monoclonal antibody
Inflammation
Kidney
Dermatology
Cell
People also interested in
PathologyCardiologyDermatologyBiomedicineInsulinClinical trialDrug targetBiomedical engineeringOptoelectronicsCell